Related
Human trial·Peer-reviewed
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · 1 Oct · Koning M, Kovynev A, Fondevila MF et al.
Animals·Preprint
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · 28 Sept · Torres G, Salladay-Perez IA, Deng CY et al.
Humans·Preprint
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · 1 Oct · Simpson DJ, Crofts SJ, Mavrommatis C et al.
Animals·Peer-reviewed
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · 1 Oct · Deng J, Zeng X, Guo J et al.
Human trial·Peer-reviewed
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · 1 Oct · Zhao S, Kuo CL, Lenze EJ et al.
